{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-26-000103","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-08-06T20:08:16+00:00","discovered_at":"2026-08-06T20:09:00.255357+00:00","generated_at":"2026-08-06T20:09:18.097794+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Halozyme reports record Q2 2026: revenue $481M (+48% YoY), raises full-year guidance","bullets":["Q2 total revenue $481M (+48% YoY); royalty revenue $308M (+50% YoY); GAAP diluted EPS $1.90, non-GAAP $2.28.","Adjusted EBITDA $329M (+46% YoY); operating income $288M.","Raised FY2026 guidance: total revenue $1.835-1.910B, royalty $1.220-1.245B, non-GAAP EPS $8.65-9.00.","Signed five new ENHANZE/Hypercon collaborations YTD (Vertex, Oruka, GSK, Incyte, undisclosed), exceeding full-year goal of three.","Repurchased $333M of shares in Q2 at avg $69.30; new $1B buyback program announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-26-000103","json":"https://secwatch.observer/filing/0001159036-26-000103.json","markdown":"https://secwatch.observer/filing/0001159036-26-000103.md","text":"https://secwatch.observer/filing/0001159036-26-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000103/0001159036-26-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000103/halo-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:09:18.097794+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}